Users can now access private company data from theJP Jenkins marketplace

Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Don't want ads? Click here
Sponsored Content
Don't want ads? Click here

Pin to quick picksIQ-AI Share News (IQAI)

Share Price Information for IQ-AI (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.845
Bid: 0.82
Ask: 0.87
Change: 0.00 (0.00%)
Spread: 0.05 (6.098%)
Open: 0.845
High: 0.845
Low: 0.845
Prev. Close: 0.845
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Timelines are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Trident Royalties swings to profit

Thu, 02nd May 2024 15:45

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Trident Royalties PLC - diversified mining royalty company - Operating loss in 2023 narrows to USD1.1 million from USD1.7 million a year earlier. Swings to pretax profit of GBP3.8 million from a loss of GBP4.6 million. "The last year has been challenging for the global financial industry: in 2022, geopolitical tensions rose with a war in Ukraine and then, in 2023, war broke out in the Middle East. Both have potential for escalation, as we have seen with the recent attacks on ships in the Red Sea," Trident says. "Within the mining industry, we experience these rising geopolitical tensions through an ever-shrinking field on which it is prudent to invest." Notes recent positive announcements by Anson Resources Ltd in relation to its Paradox Lithium project and its Green River Lithium project. Trident holds a 2.50% net smelter return royalty over Anson's projects in the Paradox Basin.

----------

Argentex Group PLC - international provider of foreign exchange services for institutions, corporates and high-net-worth private individuals - Revenue in 2023 falls to GBP49.9 million from GBP41.0 million in the 9 months ended December 31, 2022. Pretax profit falls to GBP7.3 million from GBP7.8 million. Pays out total dividend of 0.75p per share, down from 2.25p per share for 9 months to December 31. Following the completion of its strategic review, Argentex said it is "excited by the multiple opportunities for future growth." It adds: "The business operates within a large addressable market and benefits from a strong brand and reputation, as demonstrated by the fact that we have continued to grow the number of active customers during the period." Says adverse market conditions experienced during 2023 continued into the first quarter of 2024, but felt "encouraged" more recently.

----------

UK Oil & Gas PLC - oil and gas with assets in UK and Turkey - Receives a notice from RiverFort Global Opportunities PCC Ltd and YA II PN Ltd that they have converted the 200.0 million equity shares issued at an average price of approximately 0.0405 pence per share. Also issues investors a further 152.8 million shares to repay a further GBP46,603 of loan. Principal balance now stands at GBP420,000.

----------

Personal Group Holdings PLC - Milton Keynes-based employee benefits and services provider - Says it has "enjoyed continued momentum" in first quarter of 2024. "The strong performance in new insurance sales in 2023 has continued into 2024, achieving year on year growth in key sales metrics. The Benefits division has won new customers and the migration of Sage customers onto the next generation of the Hapi Employee Benefits platform is complete. As previously announced in March, the group's Pay & Reward division secured its largest consulting contract to date with a global airline, both adding to the group's recurring revenues and increasing profile within its sector," the company says. Looking ahead, remains confident in ability to deliver profitable growth in the current year, in line with market expectations.

----------

Galileo Resources PLC - Mining company focused on Zambia, Zimbabwe, Botswana, South Africa - Receives second tranche payment of ZAR48.8 million, about GBP2.1 million, for Glenover sale. Says a further ZAR5.7 million is due to be received in early May.

----------

IQ-AI Ltd - Medical services firm and parent company of Wisconsin-based healthcare imaging software firm Imaging Biometrics LLC - Wholly owned subsidiary Imaging Biometrics LLC receives Food & Drug Administration approval to proceed with an expanded access program for its lead therapeutic candidate, gallium maltolate. Says the EAP is for adult patients with recurrent/refractory glioblastoma who meet certain program eligibility criteria. "Considering the dismal prognosis of high-grade brain tumors, and following the encouraging safety profile and tolerance demonstrated in the ongoing phase 1 clinical trial at the Medical College of Wisconsin, we believe it is appropriate to initiate an EAP. This will enable more patients to potentially benefit from the treatment," says Trevor Brown, CEO of IQ-AI.

----------

Chariot Ltd - Africa-focused transitional energy company - Says drilling operations have commenced at the Loukos Onshore licence onshore Morocco, with the spud of the RZK-1 well on the Gaufrette prospect. "We are very pleased to commence this onshore campaign, kicking off the first of our exciting drilling operations for Chariot this year. We also continue to work up the prospectivity across this acreage as we see significant upside both in the vicinity of our high graded well locations and beyond," says Duncan Wallace, technical director of Chariot.

----------

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
3 Feb 2025 19:22

IN BRIEF: IQ-AI amends distribution deal with Blackford Analysis

IQ-AI Ltd - London-based medical services company - Amends existing distribution agreement with artificial intelligence platform provider Blackford Analysis Ltd. The amendment adds IB Nimble, IB ASL, IB FTB, and IB FTB Express to the agreement, allowing Blackford to also sell these products to their global client base. Acquired by Bayer in early 2023, Blackford operates in the healthcare AI platform and solutions sphere.

Read more
22 Jan 2025 17:10

IN BRIEF: IQ-AI to take GaM to phase II study, flags AI capabilities

IQ-AI Ltd - London-based medical services company - Provides operations update focusing on artificial intelligence. Explains radiology leads the way in Food & Drug Administration approvals for AI-enabled products as the FDA has increased efforts to keep pace with the advancements in AI technology. The company believes its subsidiary, Imaging Biometrics LLC, is in a unique position to lead this transformation for neuro-oncology in 2025 and beyond. Points to the imminent release of the new version of IB Clinic; its FDA-cleared suite of quantitative imaging solutions will include the incorporation of an AI model, which will greatly improve diagnostic accuracy and speed. In addition, notes the first half of 2025 should mark the next release of IB Nimble with the functionality to view IB's AI-generated images and other images within the mobile app. Also, in 2025 we anticipate releasing a new product leveraging arterial spin labelling.

Read more
14 Oct 2024 10:05

IN BRIEF: Braveheart buys 30% stake in IQ-AI from Braveheart CEO Brown

IQ-AI Ltd - parent of Wisconsin-based Imaging Biometrics LLC, which provides quantitative imaging platforms and therapeutics for the diagnosis and treatment of patients - AIM-listed technology investor Braveheart Investment Group PLC buys a nearly 30% stake in IQ-AI from Braveheart Chief Executive Officer Trevor Brown. Braveheart buys 45.8 million IQ-AI shares from Brown at 1.1 pence per share, worth GBP503,372, and another 19.7 million shares owned by Brown's children at the same price, worth GBP216,203. The two purchases give Braveheart a 29.5% stake in IQ-AI. Braveheart on Friday says the related-party transaction is approved by its independent shareholders because the IQ-AI business fits Braveheart's investment strategy and the purchase is at "an attractive entry price".

Read more
16 Aug 2024 20:40

TRADING UPDATES: NetScientific loss narrows; Vinanz ups Bitcoin fleet

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and Wednesday and not separately reported by Alliance News:

Read more
25 Jun 2024 11:56

IN BRIEF: IQ-AI subsidiary opens expanded access programme

IQ-AI Ltd - London-based medical services company - US-based subsidiary Imaging Biometrics LLC says that US Food & Drug Administration has approved an expanded access programme for oral gallium maltolate. This EAP will run in parallel with the current phase 1 clinical trial being conducted at the Medical College of Wisconsin. Explains that "As the phase 1 trial concludes this fall and while the data is being compiled, eligible patients in the US will have the option of participating in the EAP."

Read more
14 Jun 2024 14:32

IQ-AI team begins defining phase 2 protocol for oral gallium maltolate

(Alliance News) - IQ-AI Ltd on Friday said the clinical team has started a phase 2 protocol for its oncology-focused drug oral gallium maltolate, which could be a therapeutic agent for cancer.

Read more
23 May 2024 21:08

TRADING UPDATES: Celadon ships to US; Oxford BioDynamics-Goodbody pact

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
20 May 2024 11:16

IQ-AI subsidiary gets second FDA rare paediatric disease designation

(Alliance News) - IQ-AI Ltd on Monday said its subsidiary, Imaging Biometrics LLC, received a second rare paediatric disease designation by the US Food & Drug Administration for its IB-003 lead drug candidate oral gallium maltolate.

Read more
17 May 2024 17:39

TRADING UPDATES: Ingenta trades in line; Triple Point Social NAV up

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Friday and not separately reported by Alliance News:

Read more
10 May 2024 15:14

IQ-AI subsidiary gets rare paediatric disease designation FDA

(Alliance News) - IQ-AI Ltd on Friday said its subsidiary, Imaging Biometrics LLC, has been granted rare paediatric disease designation by the US Food & Drug Administration for its lead drug candidate, IB-003, or gallium maltolate for the treatment of ATRT.

Read more
22 Feb 2024 14:02

IN BRIEF: IQ-AI shares sink on discounted placing fundraise

IQ-AI Ltd - Medical services firm and parent company of Wisconsin-based healthcare imaging software firm Imaging Biometrics LLC - Announces placing to raise GBP300,000 gross proceeds via the issue of 20.0 million new shares at a price of 1.5p each. The issue price represents a discount of 32% to the company's Wednesday closing price of 2.2p. The placing includes a broker option for existing shareholders for up to 6.7 million new shares, which would raise an additional GBP100,000. Admission of the new placing and broker option shares is expected to occur on or around March 1.

Read more
9 Feb 2024 13:38

IQ-AI subsidiary asked by FDA to resubmit and modify application

(Alliance News) - IQ-AI Ltd on Friday said its subsidiary Imaging Biometric LLC will modify and resubmit its application to the US Food & Drug Administration.

Read more
2 Feb 2024 08:56

IN BRIEF: IQ-AI celebrates USD100,000 grant for subsidiary

IQ-AI Ltd - St Helier, Jersey-based medical services firm - Says that Imaging Biometrics LLC, a wholly-owned subsidiary of IQ-AI, has been given a USD100,000 grant by the Musella Foundation For Brain Tumor Research & Information Inc. Explains that the grant will help to support the launch of an intermediate group expanded access programme, which is focused on giving brain tumour patients access to oral gallium maltolate, outside of an ongoing Phase One clinical trial at the Medical College of Wisconsin. The grant will be used to facilitate the expanded access programme, including writing and submitting the study protocol, patient screening and on-boarding.

Read more
10 Jan 2024 11:48

IQ-AI falls after subsidiary notes launch of treatment access scheme

(Alliance News) - IQ-AI Ltd shares fell on Wednesday, after it said its subsidiary Imaging Biometrics LLC is launching an intermediate population cohort expanded access programme for oral gallium maltolate.

Read more

Free Investment Tools

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.